berotek has been researched along with Cardiovascular Stroke in 8 studies
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmet, I | 4 |
| Turner, T | 1 |
| Lakatta, EG | 4 |
| Talan, MI | 4 |
| Krawczyk, M | 2 |
| Heller, P | 1 |
| Moon, C | 1 |
| Zhu, W | 1 |
| Woo, AY | 1 |
| Morrell, C | 1 |
| Poosala, S | 1 |
| Xiao, RP | 1 |
| Irmer, M | 1 |
| Wollschläger, H | 1 |
| Just, H | 1 |
| Schött, D | 1 |
| Micklefield, GH | 1 |
| Ulmer, WT | 1 |
| Magnus, O | 1 |
| Türck, D | 1 |
| Dominiak, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of (R, R') and (S,S': R,R')- Fenoterol: Initial Clinical Evaluation for Pharmacokinetics, Pharmacodynamics, and Safety[NCT01440335] | Phase 1 | 29 participants (Actual) | Interventional | 2011-07-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berotek and Cardiovascular Stroke
| Article | Year |
|---|---|
[Clinical aspects and therapy of pulmonary heart disease].
Topics: Airway Resistance; Diagnosis, Differential; Drug Therapy, Combination; Fenoterol; Humans; Ipratropiu | 1990 |
7 other studies available for berotek and Cardiovascular Stroke
| Article | Year |
|---|---|
Fenoterol enantiomers do not possess beneficial therapeutic properties of their racemic mixture in the rat model of post myocardial infarction dilated cardiomyopathy.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Cardiomyopathy, Dilated; Coronary Vessels; Echocardiog | 2012 |
Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 2004 |
Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2005 |
Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 2008 |
[Treatment of severe congestive heart failure with the beta-agonist fenoterol (author's transl)].
Topics: Adrenergic beta-Agonists; Adult; Aged; Cardiac Output, Low; Coronary Disease; Ethanolamines; Female; | 1981 |
[Myocardial infarction during tocolysis with sympathomimetics].
Topics: Adult; Female; Fenoterol; Humans; Infant, Newborn; Myocardial Infarction; Obstetric Labor, Premature | 1987 |
Changes in cardiovascular adrenoceptor response in rats subsequent to myocardial infarction.
Topics: Animals; Blood Pressure; Cardiovascular System; Decerebrate State; Electric Stimulation; Epinephrine | 1987 |